Skip to main content
. 2017 Aug 25;8:1024. doi: 10.3389/fimmu.2017.01024

Figure 1.

Figure 1

Immunomodulatory monoclonal antibodies and combination strategies in cutaneous melanoma immunotherapy. Different immunotherapeutic strategies are currently being assessed in combination in clinical trials that either “push” tumor immunoreactivity or “release” from inhibitory immune-regulatory mechanisms, fostering this way an antitumor immune response.